awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
Graphs
1
Q33871868-3BDCC853-2441-4FE5-9D52-0C5B6714B12C
Q33871868-3BDCC853-2441-4FE5-9D52-0C5B6714B12C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33871868-3BDCC853-2441-4FE5-9D52-0C5B6714B12C
The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
P2860
Q33871868-3BDCC853-2441-4FE5-9D52-0C5B6714B12C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33871868-3BDCC853-2441-4FE5-9D52-0C5B6714B12C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
205e6b5141a1e2b403d427c647b0de47564ea535
P2860
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days